03/05/2025
Strengthening Global Partnerships: Maxima Biotech x WPI
Maxima Biotech is proud to continue its strategic collaboration with Worcester Polytechnic Institute (WPI) for the fourth consecutive year. This partnership, initiated by Taiwan’s National Science and Technology Council 國家科學及技術委員會, plays a key role in strengthening our global market strategy and intellectual property (IP) capabilities.
This year, a WPI student team is conducting in-depth market analysis and patent risk assessments, using our cordless ultrasonic dissector as a practical case study. Their research focuses on post–patent cliff dynamics and Freedom to Operate (FTO) strategies—critical for successful global commercialization and licensing.
We’re excited to host the WPI team for a seven-week field study in Taiwan, including visits to our R&D center to explore our next-generation high-energy electrosurgical technologies. Their final presentation is scheduled for May 2nd.
At Maxima, we pursue two core strategies to serve the global healthcare market:
Helper Strategy: Acting as an agile partner for global medtech leaders, accelerating validation through platforms like IRCAD and our proprietary technologies.
Turnkey Export Model: Helping global partners establish local manufacturing, enhancing medical supply chain resilience.
This partnership is more than an academic exchange—it’s part of our long-term commitment to make minimally invasive surgery more Available, Accessible, and Affordable worldwide.
